ALRN

Aileron Therapeutics, Inc.

5.03 USD
-0.10 (-1.95%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Aileron Therapeutics, Inc. stock is up 6.79% since 30 days ago. The next earnings date is Mar 18, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 March’s closed higher than February.

About Aileron Therapeutics, Inc.

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. Company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma.